AP2012006192A0 - PyrroloÄ2,3-DÜ pyrimidine compounds. - Google Patents
PyrroloÄ2,3-DÜ pyrimidine compounds.Info
- Publication number
- AP2012006192A0 AP2012006192A0 AP2012006192A AP2012006192A AP2012006192A0 AP 2012006192 A0 AP2012006192 A0 AP 2012006192A0 AP 2012006192 A AP2012006192 A AP 2012006192A AP 2012006192 A AP2012006192 A AP 2012006192A AP 2012006192 A0 AP2012006192 A0 AP 2012006192A0
- Authority
- AP
- ARIPO
- Prior art keywords
- pyrroloä2
- pyrimidine compounds
- pyrimidine
- compounds
- Prior art date
Links
- 150000003230 pyrimidines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25203909P | 2009-10-15 | 2009-10-15 | |
| PCT/IB2010/054447 WO2011045702A1 (en) | 2009-10-15 | 2010-10-01 | Pyrrolo[2,3-d] pyrimidine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AP2012006192A0 true AP2012006192A0 (en) | 2012-04-30 |
Family
ID=43413616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AP2012006192A AP2012006192A0 (en) | 2009-10-15 | 2010-10-01 | PyrroloÄ2,3-DÜ pyrimidine compounds. |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US8633206B2 (enExample) |
| EP (1) | EP2488524B1 (enExample) |
| JP (1) | JP5629324B2 (enExample) |
| KR (1) | KR20120083452A (enExample) |
| CN (1) | CN102574860A (enExample) |
| AP (1) | AP2012006192A0 (enExample) |
| AR (1) | AR078635A1 (enExample) |
| AU (1) | AU2010308028A1 (enExample) |
| CA (1) | CA2776028C (enExample) |
| CL (1) | CL2012000795A1 (enExample) |
| CO (1) | CO6531451A2 (enExample) |
| CR (1) | CR20120164A (enExample) |
| CU (1) | CU20120059A7 (enExample) |
| DO (1) | DOP2012000080A (enExample) |
| EA (1) | EA201290147A1 (enExample) |
| EC (1) | ECSP12011855A (enExample) |
| ES (1) | ES2426407T3 (enExample) |
| IL (1) | IL218802A0 (enExample) |
| IN (1) | IN2012DN02577A (enExample) |
| MA (1) | MA33670B1 (enExample) |
| MX (1) | MX2012004379A (enExample) |
| NI (1) | NI201200053A (enExample) |
| PE (1) | PE20121077A1 (enExample) |
| PH (1) | PH12012500583A1 (enExample) |
| TN (1) | TN2012000146A1 (enExample) |
| TW (1) | TWI398444B (enExample) |
| UY (1) | UY32947A (enExample) |
| WO (1) | WO2011045702A1 (enExample) |
| ZA (1) | ZA201202718B (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9394333B2 (en) | 2008-12-02 | 2016-07-19 | Wave Life Sciences Japan | Method for the synthesis of phosphorus atom modified nucleic acids |
| BRPI1013559A2 (pt) | 2009-03-23 | 2016-04-12 | Glenmark Pharmaceuticals Sa | compostos, composição farmacêutica, método de tratamento de doença ou condição associada à função trpa1 e respectivos usos |
| EP2411395B1 (en) | 2009-03-23 | 2013-05-29 | Glenmark Pharmaceuticals S.A. | Furopyrimidinedione derivatives as trpa1 modulators |
| MX342945B (es) | 2009-07-06 | 2016-10-18 | Ontorii Inc * | Profármacos de ácido nucleico novedosos y métodos de uso de los mismos. |
| TW201111385A (en) * | 2009-08-27 | 2011-04-01 | Biocryst Pharm Inc | Heterocyclic compounds as janus kinase inhibitors |
| WO2011075334A1 (en) * | 2009-12-18 | 2011-06-23 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine compounds |
| DK2620428T3 (da) * | 2010-09-24 | 2019-07-01 | Wave Life Sciences Ltd | Asymmetrisk hjælpegruppe |
| US9605019B2 (en) | 2011-07-19 | 2017-03-28 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
| PH12013502670A1 (en) | 2011-08-12 | 2016-07-29 | Nissan Chemical Ind Ltd | Tricyclic heterocyclic compounds and jak inhibitors |
| SG11201500243WA (en) | 2012-07-13 | 2015-04-29 | Shin Nippon Biomedical Lab Ltd | Chiral nucleic acid adjuvant |
| KR20240148947A (ko) | 2012-07-13 | 2024-10-11 | 웨이브 라이프 사이언시스 리미티드 | 키랄 제어 |
| SG11201500239VA (en) | 2012-07-13 | 2015-03-30 | Wave Life Sciences Japan | Asymmetric auxiliary group |
| EP2875013B1 (en) * | 2012-07-17 | 2017-11-29 | Glaxosmithkline Intellectual Property (No. 2) Limited | Indolecarbonitriles as selective androgen receptor modulators |
| CN103896946B (zh) * | 2012-12-28 | 2018-04-03 | 浙江导明医药科技有限公司 | 用于预防及治疗多种自身免疫疾病的新化合物 |
| WO2014118388A1 (en) | 2013-02-04 | 2014-08-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for assaying jak2 activity in red blood cells and uses thereof |
| JP6248948B2 (ja) | 2013-02-08 | 2017-12-20 | 日産化学工業株式会社 | ３環性ピロロピリジン化合物及びｊａｋ阻害剤 |
| RS58245B1 (sr) | 2013-02-22 | 2019-03-29 | Pfizer | Kombinacija derivata pirolo[2,3-d]pirimidina sa jednim ili više dodatnih sredstava kao inhibitor janus kinaza (jak) |
| SI2991988T1 (sl) * | 2013-05-02 | 2017-09-29 | F. Hoffmann-La Roche Ag | Derivati pirolo(2,3-d)pirimidina kot agonisti receptorja CB2 |
| WO2015108048A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| EP3095460A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
| WO2015108047A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
| ES2917473T3 (es) | 2014-01-16 | 2022-07-08 | Wave Life Sciences Ltd | Diseño quiral |
| EP2924026A1 (en) | 2014-03-28 | 2015-09-30 | Novartis Tiergesundheit AG | Aminosulfonylmethylcyclohexanes as JAK inhibitors |
| AU2015260349B2 (en) | 2014-05-14 | 2019-02-21 | Nissan Chemical Industries, Ltd. | Tricyclic compound and JAK inhibitor |
| EP3180344B1 (en) | 2014-08-12 | 2019-09-18 | Pfizer Inc | Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase |
| AU2017221193B2 (en) * | 2016-02-16 | 2019-03-14 | Zoetis Services Llc | Process for preparing 7H-pyrrolo (2, 3-d) pyrimidine compounds |
| CN107098908B (zh) * | 2016-02-23 | 2021-01-08 | 欣凯医药科技(上海)有限公司 | 一种吡咯并嘧啶类化合物的制备方法和应用 |
| WO2018167283A1 (en) | 2017-03-17 | 2018-09-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling |
| EP3610264A1 (en) | 2017-04-13 | 2020-02-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma |
| WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
| FI3915989T3 (fi) | 2019-01-30 | 2023-09-20 | Felicamed Biotechnology Co Ltd | Jak:n estäjä ja sen valmistusmenetelmä |
| IL264854A (en) * | 2019-02-14 | 2020-08-31 | Bahat Anat | Spt5 inhibitors and methods of use thereof |
| CN114025758A (zh) * | 2019-07-01 | 2022-02-08 | 钱立刚 | P2x7r拮抗剂 |
| US12492204B2 (en) | 2019-08-26 | 2025-12-09 | Chemwerth, Inc. | Substituted (7H-pyrrolo[2,3-D]pyrimidin-4-yl) amino compounds useful as JAK 1 inhibitors |
| US20220372135A1 (en) | 2019-09-27 | 2022-11-24 | Disc Medicine, Inc. | Methods for treating myelofibrosis and related conditions |
| CA3177830A1 (en) | 2020-05-13 | 2021-11-18 | Maria BECONI | Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis |
| CN115246833B (zh) * | 2021-04-27 | 2024-08-13 | 洛阳惠中兽药有限公司 | 一种奥拉替尼化合物及其中间体化合物的制备方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW505646B (en) * | 1998-06-19 | 2002-10-11 | Pfizer Prod Inc | Pyrrolo [2,3-d] pyrimidine compounds |
| PA8474101A1 (es) * | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| PT1382339E (pt) | 1999-12-10 | 2008-02-06 | Pfizer Prod Inc | Composições que contêm derivados de pirrolo[2,3-d]- pirimidina |
| PL359563A1 (pl) | 2000-06-26 | 2004-08-23 | Pfizer Products Inc. | Związki pirolo [2,3-d] pirymidynowe jako środki immunosupresyjne |
| US7301023B2 (en) | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
| KR100678800B1 (ko) | 2002-11-21 | 2007-02-05 | 화이자 프로덕츠 인코포레이티드 | 3-아미노-피페리딘 유도체 및 그의 제조 방법 |
| CA2536954C (en) * | 2003-08-29 | 2012-11-27 | Exelixis, Inc. | C-kit modulators and methods of use |
| CA2546192C (en) | 2003-11-17 | 2010-04-06 | Pfizer Products Inc. | Pyrrolopyrimidine compounds useful in treatment of cancer |
| EP1725562A1 (en) | 2004-03-05 | 2006-11-29 | Taisho Pharmaceutical Co., Ltd | Pyrrolopyrimidine derivatives |
| JP5368701B2 (ja) * | 2004-07-02 | 2013-12-18 | エクセリクシス、インコーポレイテッド | ｃ−Ｍｅｔモジュレーター及び使用方法 |
| AR054416A1 (es) * | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
| AU2006254840B2 (en) | 2005-06-08 | 2012-08-02 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
| CN102127078A (zh) | 2005-07-14 | 2011-07-20 | 安斯泰来制药株式会社 | Janus激酶3的杂环类抑制剂 |
| CA2614907C (en) | 2005-07-29 | 2012-02-28 | Pfizer Products Inc. | Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis |
| EP2532667A1 (en) | 2005-09-30 | 2012-12-12 | Vertex Pharmaceuticals Incorporated | Deazapurines useful as inhibitors of janus kinases |
| NZ567851A (en) | 2005-11-01 | 2011-09-30 | Targegen Inc | Bi-aryl meta-pyrimidine inhibitors of kinases |
| ES2622493T3 (es) | 2006-02-24 | 2017-07-06 | Rigel Pharmaceuticals, Inc. | Composiciones y métodos para la inhibición de la ruta de JAK |
| CA2644809A1 (en) * | 2006-03-02 | 2007-09-07 | Astellas Pharma Inc. | 17 .beta. hsd type 5 inhibitor |
| WO2009049028A1 (en) | 2007-10-09 | 2009-04-16 | Targegen Inc. | Pyrrolopyrimidine compounds and their use as janus kinase modulators |
| WO2009115084A2 (de) | 2008-03-20 | 2009-09-24 | Schebo Biotech Ag | Neue pyrrolopyrimidin-derivate und deren verwendungen |
| EP2384326B1 (en) * | 2008-08-20 | 2014-04-23 | Zoetis LLC | Pyrrolo[2,3-d]pyrimidine compounds |
-
2010
- 2010-10-01 EA EA201290147A patent/EA201290147A1/ru unknown
- 2010-10-01 CA CA2776028A patent/CA2776028C/en not_active Expired - Fee Related
- 2010-10-01 ES ES10771200T patent/ES2426407T3/es active Active
- 2010-10-01 EP EP10771200.2A patent/EP2488524B1/en active Active
- 2010-10-01 WO PCT/IB2010/054447 patent/WO2011045702A1/en not_active Ceased
- 2010-10-01 AU AU2010308028A patent/AU2010308028A1/en not_active Abandoned
- 2010-10-01 KR KR1020127012417A patent/KR20120083452A/ko not_active Ceased
- 2010-10-01 CN CN2010800461239A patent/CN102574860A/zh active Pending
- 2010-10-01 PE PE2012000447A patent/PE20121077A1/es not_active Application Discontinuation
- 2010-10-01 MX MX2012004379A patent/MX2012004379A/es unknown
- 2010-10-01 IN IN2577DEN2012 patent/IN2012DN02577A/en unknown
- 2010-10-01 JP JP2012533715A patent/JP5629324B2/ja not_active Expired - Fee Related
- 2010-10-01 AP AP2012006192A patent/AP2012006192A0/xx unknown
- 2010-10-01 PH PH1/2012/500583A patent/PH12012500583A1/en unknown
- 2010-10-12 TW TW099134779A patent/TWI398444B/zh not_active IP Right Cessation
- 2010-10-13 US US12/903,554 patent/US8633206B2/en active Active
- 2010-10-14 AR ARP100103751A patent/AR078635A1/es not_active Application Discontinuation
- 2010-10-15 UY UY0001032947A patent/UY32947A/es not_active Application Discontinuation
-
2012
- 2012-03-22 IL IL218802A patent/IL218802A0/en unknown
- 2012-03-23 DO DO2012000080A patent/DOP2012000080A/es unknown
- 2012-03-29 TN TNP2012000146A patent/TN2012000146A1/fr unknown
- 2012-03-30 CR CR20120164A patent/CR20120164A/es unknown
- 2012-03-30 CL CL2012000795A patent/CL2012000795A1/es unknown
- 2012-04-09 NI NI201200053A patent/NI201200053A/es unknown
- 2012-04-13 CU CU20120059A patent/CU20120059A7/es unknown
- 2012-04-13 MA MA34774A patent/MA33670B1/fr unknown
- 2012-04-13 ZA ZA2012/02718A patent/ZA201202718B/en unknown
- 2012-04-18 CO CO12064126A patent/CO6531451A2/es not_active Application Discontinuation
- 2012-04-27 EC ECSP12011855 patent/ECSP12011855A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP2012006192A0 (en) | PyrroloÄ2,3-DÜ pyrimidine compounds. | |
| AP2011005987A0 (en) | Antiviral compounds. | |
| SI2384326T1 (sl) | Pirolo(2,3-d)pirimidinske spojine | |
| AP2011005706A0 (en) | New compounds. | |
| AP2012006216A0 (en) | Benzimidazole-imidazole derivatives. | |
| BRPI1013760A2 (pt) | compostos anticâncer de amino pirimidina. | |
| AP2010005415A0 (en) | Catalysts. | |
| IL213002A0 (en) | Reciprocally-cycled, externally-actuated weapon | |
| AP2011005852A0 (en) | Novel herbicides. | |
| AP2011005799A0 (en) | Novel herbicides. | |
| AP2011005770A0 (en) | Catalysts. | |
| AP2011005850A0 (en) | Novel herbicides. | |
| AP2011005894A0 (en) | 5-alkynyl-pyridines. | |
| SI2266990T1 (sl) | Spojina 3-fenilpirazolo(5,1-b)tiazola | |
| AP2011005932A0 (en) | Pyrazinoisoquinoline Compounds. | |
| AP2012006221A0 (en) | Compounds useful against kinetoplastideae parasites. | |
| PL2519504T3 (pl) | Nowe drugorzędowe pochodne 8-hydroksychinolino-7-karboksyamidu | |
| GB2476715B (en) | Eco-F.E.W.L. | |
| IL213762A0 (en) | 1,1,1-trifluoro-2-hydroxypropyl compounds | |
| AP2011005789A0 (en) | Sulfamoyl-phenyl-ureido benzamidine-derivatives asantimalarial agents. | |
| AP2011005899A0 (en) | Plaswall. | |
| GB0903558D0 (en) | . | |
| GB0918988D0 (en) | . | |
| GB0902615D0 (en) | . | |
| GB201020866D0 (en) | . |